Results 1 to 10 of about 901 (171)
HIV/AIDS - Research and Palliative Care, 2016 Rustin D Crutchley,1 Rakesh C Guduru,2 Amy M Cheng1 1Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, 2CompanionDX, Houston, TX, USA Abstract: Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (
Rustin D Crutchley
exaly +8 more sources
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection
Clinical Therapeutics, 2015 This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy and tolerability, drug interactions, and dosing and administration of cobicistat.Searches of MEDLINE and International Pharmaceutical Abstracts from 1964 to February 2015 were conducted using the search terms cobicistat and GS-9350 ...
Elizabeth M Sherman +2 more
exaly +5 more sources
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters [PDF]
mBio, 2022 Combinations of direct-acting antivirals are needed to minimize drug resistance mutations and stably suppress replication of RNA viruses. Currently, there are limited therapeutic options against the severe acute respiratory syndrome coronavirus 2 (SARS ...
Iart Luca Shytaj +28 more
doaj +3 more sources
Mild self-declared side effects of boosted darunavir associated with other antiretrovirals in Romanian HIV-1 infected patients [PDF]
Archives of the Balkan Medical Union, 2021 Introduction. Antiretroviral therapy (ART) is used in human immunodeficiency virus (HIV)-infected patients, to suppress viral replication and slow disease progression.
Ruxandra C. MARIN +2 more
doaj +1 more source
Biomedicines, 2021 The management of the side effects caused by the antiretroviral therapy is one of the main problems facing clinicians. The patient’s tolerability and safety influence the success of the therapy.
Ruxandra-Cristina Marin +4 more
doaj +1 more source
Pharmacokinetic Boosting of Kinase Inhibitors
Pharmaceutics, 2023 (1) Introduction: Pharmacokinetic boosting of kinase inhibitors can be a strategy to enhance drug exposure and to reduce dose and associated treatment costs.
Niels Westra +4 more
doaj +1 more source
Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches [PDF]
Advanced Pharmaceutical Bulletin, 2023 Purpose: Drug repurposing is an approach successfully used for discovery of new therapeutic applications for the existing drugs. The current study was aimed to use the combination of in silico methods to identify FDA-approved drugs with possible S1P1 ...
Ali Akbar Alizadeh +2 more
doaj +1 more source
Clinical and Translational Science, 2021 The inhibitor of anaplastic lymphoma kinase (ALK) crizotinib significantly increases survival in patients with ALK‐positive non‐small cell lung cancer (NSCLC).
Nicolas Hohmann +7 more
doaj +1 more source
EBioMedicine, 2022 Summary: Background: SJ733, a newly developed inhibitor of P. falciparum ATP4, has a favorable safety profile and rapid antiparasitic effect but insufficient duration to deliver a single-dose cure of malaria.
Aditya H. Gaur +21 more
doaj +1 more source
Future Journal of Pharmaceutical Sciences, 2022 Background The present research article involves the simultaneous determination of Tenofovir alafenamide, Darunavir, Emtricitabine and Cobicistat in bulk as well as in tablet dosage form using high performance liquid chromatography. Result The separation
Challamalla Pavani, E. Susithra
doaj +1 more source